DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma.
We previously described PASD1 as a new cancer testis antigen in multiple myeloma (MM) that is retained post-therapy, suggesting the use of vaccination strategies to induce anti-PASD1 immunity in a setting of minimal residual disease. We have focused on DNA fusion gene vaccines, coupling fragment C d...
主要な著者: | Joseph-Pietras, D, Gao, Y, Zojer, N, Ait-Tahar, K, Banham, A, Pulford, K, Rice, J, Savelyeva, N, Sahota, S |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2010
|
類似資料
-
PASD1 is a potential multiple myeloma-associated antigen.
著者:: Sahota, S, 等
出版事項: (2006) -
Cytotoxic T-Cell Response to the Cancer Testis Antigen PASD1 In Multiple Myeloma: PASD1 Peptides for a Generic Vaccine to Treat PASD1-Positive Haematological Malignancies.
著者:: Campbell, A, 等
出版事項: (2010) -
PASD1, a DLBCL-associated cancer testis antigen and candidate for lymphoma immunotherapy.
著者:: Cooper, C, 等
出版事項: (2006) -
Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma.
著者:: Ait-Tahar, K, 等
出版事項: (2009) -
Cytotoxic T-cell response to the PASD1 protein in patients with diffuse large B-cell lymphoma
著者:: Ait-Tahar, K, 等
出版事項: (2009)